Physician profile
Gary V Gordon
NPI 1225065774
$95,016.57
in general payments reported to CMS, 2019-2025
46 companies · $12K in 2025
The $12K reported for 2025 was more than what 91% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $17K · 2021: $5,308 · 2022: $6,652 · 2023: $5,836 · 2024: $6,081 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,161.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,542.50 |
| Education | $367.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $22,916.80 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $21,909.56 | 2019 | |
| Abbvie INC. | $17,422.41 | 2019-2025 | |
| Amgen INC. | $11,399.95 | 2019-2025 | Otezla, Evenity, Enbrel |
| Celgene Corporation | $3,955.64 | 2019 | |
| Ucb, INC. | $2,126.32 | 2019-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $2,056.63 | 2021-2025 | Saphnelo |
| Pfizer INC. | $1,574.99 | 2019-2025 | |
| Radius Health, INC. | $1,333.35 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $1,190.48 | 2019-2025 | |
| Janssen Biotech, INC. | $1,171.23 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $1,052.53 | 2019-2025 | Orencia |
| Lilly USA, LLC | $882.24 | 2019-2025 | Taltz, Zepbound |
| Genentech USA, INC. | $845.49 | 2019-2025 | Actemra, Rituxan, Erivedge |
| Glaxosmithkline, LLC. | $756.48 | 2019-2025 | Benlysta |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $639.17 | 2021-2024 | Cyltezo, Ofev |
| Ani Pharmaceuticals, INC. | $543.99 | 2022-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $526.15 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $407.55 | 2021-2024 | Lupkynis |
| Horizon Therapeutics Plc | $307.17 | 2019-2022 | |
| Organon LLC | $252.00 | 2024-2025 | Hadlima, Renflexis |
| Actelion Pharmaceuticals US, INC. | $176.63 | 2023 | Uptravi, Opsumit |
| Sandoz INC. | $174.77 | 2023-2025 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $155.14 | 2019-2024 | Strensiq |
| Kiniksa Pharmaceuticals, LTD. | $140.11 | 2022-2023 | Arcalyst |
| Zimmer Biomet Holdings, INC. | $116.98 | 2022-2025 | Gel-One Cross-Linked Hyaluronate |
| Pacira Therapeutics, INC. | $102.93 | 2019-2020 | |
| Kyowa Kirin, INC. | $99.47 | 2023-2024 | Crysvita |
| Celltrion USA INC. | $87.72 | 2023 | Yuflyma |
| Depuy Synthes Sales INC. | $82.08 | 2019-2025 | Orthovisc, Monovisc |
| Sobi, INC | $80.89 | 2019-2022 | |
| Medexus Pharma, INC. | $64.23 | 2019 | |
| Novo Nordisk INC | $63.98 | 2023-2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $59.99 | 2019 | |
| Almatica Pharma LLC | $57.67 | 2024-2025 | Teriparatide |
| Hikma Pharmaceuticals USA | $46.84 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $45.82 | 2024 | Belbuca, Xtampza |
| Ultragenyx Pharmaceutical INC. | $34.92 | 2021-2023 | |
| Tonix Medicines, INC. | $26.26 | 2025 | Tonmya |
| Kiniksa Pharmaceuticals International, Plc | $25.38 | 2024 | Arcalyst |
| Invivyd INC | $23.07 | 2024 | Pemgarda |
| Alvogen INC | $20.87 | 2024 | Teriparatide |
| Sebela Pharmaceuticals INC. | $17.57 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.12 | 2023 | Seglentis |
| Fresenius Kabi USA, LLC | $14.15 | 2024 | Idacio |
| Zyla Life Sciences, INC. | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.